Details for Patent: 7,727,963
✉ Email this page to a colleague
Which drugs does patent 7,727,963 protect, and when does it expire?
Patent 7,727,963 protects KORSUVA and is included in one NDA.
This patent has forty-nine patent family members in twenty-five countries.
Summary for Patent: 7,727,963
| Title: | Synthetic peptide amides |
| Abstract: | The invention relates to synthetic tetrapeptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P.sub.450 CYP inhibition and low penetration into the brain. An exemplary synthetic tetrapeptide amide of the invention is D-Phe-D-Phe-D-Leu-(.epsilon.-Me) D-Lys-[4-Amidinohomopiperazine amide]: ##STR00001## Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention. |
| Inventor(s): | Schteingart; Claudio D. (San Diego, CA), Jiang; Guangcheng (San Diego, CA), Alexander; Roberta Vezza (San Diego, CA), Sueiras-Diaz; Javier (La Jolla, CA), Luo; Zhiyong (New City, NY) |
| Assignee: | Cara Therapeutics, Inc. (Shelton, CT) |
| Application Number: | 12/176,279 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 7,727,963
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cara Therap | KORSUVA | difelikefalin acetate | SOLUTION;INTRAVENOUS | 214916-001 | Aug 23, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | TREATMENT OF MODERATE-TO-SEVERE PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD-AP) IN ADULTS UNDERGOING HEMODIALYSIS (HD) | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,727,963
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2064228 | ⤷ Sign Up | 301199 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2064228 | ⤷ Sign Up | CA 2022 00045 | Denmark | ⤷ Sign Up |
| European Patent Office | 2064228 | ⤷ Sign Up | PA2022522 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2064228 | ⤷ Sign Up | LUC00282 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2064228 | ⤷ Sign Up | 2022C/546 | Belgium | ⤷ Sign Up |
| European Patent Office | 2064228 | ⤷ Sign Up | C20220035 00379 | Estonia | ⤷ Sign Up |
| European Patent Office | 2064228 | ⤷ Sign Up | 122022000071 | Germany | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
